To test this hypothesis, we performed drug treatment with pemigatinib, an FGFR2 inhibitor49, using the SNU16m1 gastric cancer monoclonal cell line (containing MYC and FGFR2 ecDNAs that engage in intermolecular enhancer–promoter interactions4; Fig. 4h). The gene discussed is FGFR2; the disease is gastric cancer.